NO337225B1 - Vandige ciclesonidsuspensjoner for forstøving - Google Patents
Vandige ciclesonidsuspensjoner for forstøving Download PDFInfo
- Publication number
- NO337225B1 NO337225B1 NO20063047A NO20063047A NO337225B1 NO 337225 B1 NO337225 B1 NO 337225B1 NO 20063047 A NO20063047 A NO 20063047A NO 20063047 A NO20063047 A NO 20063047A NO 337225 B1 NO337225 B1 NO 337225B1
- Authority
- NO
- Norway
- Prior art keywords
- ciclesonide
- suspension
- mixtures
- excipients
- osmolality
- Prior art date
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims description 90
- 229960003728 ciclesonide Drugs 0.000 title claims description 85
- 239000000725 suspension Substances 0.000 title claims description 81
- 238000000889 atomisation Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 55
- 239000002245 particle Substances 0.000 claims description 48
- 239000007900 aqueous suspension Substances 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- -1 cyclohexylmethylene Chemical group 0.000 claims description 22
- 238000002663 nebulization Methods 0.000 claims description 22
- 239000000375 suspending agent Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229940097362 cyclodextrins Drugs 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940068965 polysorbates Drugs 0.000 claims description 4
- 229920001664 tyloxapol Polymers 0.000 claims description 4
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004224 tyloxapol Drugs 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229920001987 poloxamine Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 38
- 230000001954 sterilising effect Effects 0.000 description 38
- 238000004659 sterilization and disinfection Methods 0.000 description 36
- 229920001213 Polysorbate 20 Polymers 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
- 229940068977 polysorbate 20 Drugs 0.000 description 10
- 239000011521 glass Substances 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003862 glucocorticoid Substances 0.000 description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229940068968 polysorbate 80 Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 229960004436 budesonide Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- OXPLANUPKBHPMS-ZXBNPROVSA-N desisobutyrylciclesonide Chemical compound C1([C@@H]2O[C@@H]3C[C@H]4[C@H]5[C@@H]([C@]6(C=CC(=O)C=C6CC5)C)[C@@H](O)C[C@@]4([C@@]3(O2)C(=O)CO)C)CCCCC1 OXPLANUPKBHPMS-ZXBNPROVSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 150000001241 acetals Chemical group 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027987 antiseptic and disinfectant phenol and derivative Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000024696 nocturnal asthma Diseases 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940072266 pulmicort Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 150000003398 sorbic acids Chemical class 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03028848 | 2003-12-16 | ||
| PCT/EP2004/053495 WO2005058935A2 (en) | 2003-12-16 | 2004-12-15 | Aqueous suspensions of ciclesonide for nebulisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20063047L NO20063047L (no) | 2006-09-05 |
| NO337225B1 true NO337225B1 (no) | 2016-02-15 |
Family
ID=34684543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063047A NO337225B1 (no) | 2003-12-16 | 2006-06-30 | Vandige ciclesonidsuspensjoner for forstøving |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20070117783A1 (enExample) |
| EP (2) | EP2319858B1 (enExample) |
| JP (1) | JP5001657B2 (enExample) |
| KR (1) | KR101086095B1 (enExample) |
| CN (1) | CN100513417C (enExample) |
| AR (1) | AR046892A1 (enExample) |
| AU (1) | AU2004298447B2 (enExample) |
| BR (1) | BRPI0416854B8 (enExample) |
| CA (1) | CA2549038C (enExample) |
| CO (1) | CO5700832A2 (enExample) |
| EA (1) | EA012388B1 (enExample) |
| EC (1) | ECSP066608A (enExample) |
| IL (1) | IL175461A (enExample) |
| MY (1) | MY159377A (enExample) |
| NO (1) | NO337225B1 (enExample) |
| NZ (1) | NZ547217A (enExample) |
| PE (1) | PE20050941A1 (enExample) |
| TW (1) | TWI350757B (enExample) |
| UA (1) | UA87123C2 (enExample) |
| WO (1) | WO2005058935A2 (enExample) |
| ZA (1) | ZA200603768B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022796A1 (en) * | 2007-08-07 | 2009-02-11 | Nycomed GmbH | Amorphous ciclesonide |
| US7984792B2 (en) * | 2008-03-03 | 2011-07-26 | Rolls-Royce Corporation | Lubrication system |
| EP2359845A4 (en) * | 2008-12-03 | 2015-05-27 | Ltt Bio Pharma Co Ltd | INHALANT COMPRISING A MODIFIED SUPERMEDASE SUPERMEDASE |
| AU2010289417B2 (en) | 2009-09-02 | 2015-08-13 | Synedgen, Inc. | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| HUE058753T2 (hu) * | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| AU2012296938A1 (en) | 2011-08-12 | 2014-02-13 | Boehringer Ingelheim Vetmedica Gmbh | Funny current (IF) inhibitors for use in a method of treating and preventing heart failure in feline |
| CA2844944A1 (en) | 2011-08-18 | 2013-02-21 | Takeda Gmbh | Pharmaceutical aerosol product for administration by oral or nasal inhalation |
| CN103917223B (zh) | 2011-09-14 | 2017-08-08 | 盐野义制药株式会社 | 供吸入的药用组合物 |
| US20140179651A1 (en) | 2012-12-21 | 2014-06-26 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
| ES2909039T3 (es) | 2012-12-21 | 2022-05-05 | Boehringer Ingelheim Vetmedica Gmbh | Formulación farmacéutica que comprende ciclesonida |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| HUE051527T2 (hu) | 2014-06-18 | 2021-03-01 | Boehringer Ingelheim Vetmedica Gmbh | Muszkarin-antagonisták és kombinációik légúti betegség lovakban történõ kezelésére |
| EP4420518A3 (en) * | 2014-09-11 | 2024-11-20 | Synedgen, Inc. | Compositions and methods of use thereof |
| HK1252798A1 (zh) * | 2015-08-05 | 2019-06-06 | Daiichi Sankyo Company, Limited | 喷雾器用组合物 |
| CN106692163A (zh) * | 2015-11-13 | 2017-05-24 | 天津金耀集团有限公司 | 一种吸入用环索奈德混悬液组合物 |
| WO2019090405A1 (pt) * | 2017-11-11 | 2019-05-16 | Carvalho Junior Mario Virgilio De | Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza |
| WO2020123336A1 (en) * | 2018-12-13 | 2020-06-18 | Qrumpharma Inc. | Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them |
| US20210346613A1 (en) * | 2020-05-05 | 2021-11-11 | Mahesh Kumar KHAITAN | Controlled delivery device for treating coronavirus infections and methods thereof |
| US20220031712A1 (en) * | 2020-06-23 | 2022-02-03 | Cai Gu Huang | Preparation of a pharmaceutical composition of olodaterol and budesonide |
| WO2022213101A1 (en) * | 2021-04-01 | 2022-10-06 | Vitrean Inc. | Methods for manufacturing of highly concentrated hydrogels |
| WO2022231533A1 (en) * | 2021-04-29 | 2022-11-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Process for the preparation of sterilized suspensions for the inhalation by nebulization |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6392036B1 (en) * | 1997-11-14 | 2002-05-21 | Astrazeneca Ab | Dry heat sterilization of a glucocorticosteroid |
| WO2004004739A1 (en) * | 2002-07-02 | 2004-01-15 | Altana Pharma Ag | Ciclesonide-containing sterile aqueous suspension |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE458986B (sv) * | 1985-03-29 | 1989-05-29 | Draco Ab | Dosfoerpackning |
| SE8600632D0 (sv) * | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| GR1001529B (el) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| RU2132854C1 (ru) | 1993-04-02 | 1999-07-10 | Бик Гульден Ломберг Хемише Фабрик ГмбХ | Производные преднизолона, способ их получения и лекарственное средство |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| GB9410222D0 (en) | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| DE19541689A1 (de) | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Kombinationsarzneimittel |
| DE19635498A1 (de) | 1996-09-03 | 1998-03-26 | Byk Gulden Lomberg Chem Fab | Verfahren zur Epimerenanreicherung |
| US6120752A (en) | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
| US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6264923B1 (en) | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
| WO1999061001A1 (en) | 1998-05-29 | 1999-12-02 | Rtp Pharma Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
| US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| IT1303692B1 (it) | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
| IT1313553B1 (it) * | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| AR026073A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| AU7947600A (en) | 1999-10-20 | 2001-04-30 | Teijin Limited | Aqueous medicinal compositions |
| AR026072A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
| DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| ATE330638T1 (de) * | 2000-11-24 | 2006-07-15 | Breath Ltd | Sterilisation von glucocorticosteriodsuspensionen |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| DE10145361A1 (de) * | 2001-09-14 | 2003-04-03 | Pari Gmbh | Verfahren zur Herstellung von flüssigen, sterilen Zubereitungen zur Inhalation |
| AU2002350622B2 (en) | 2001-10-24 | 2006-09-14 | Pari Pharma Gmbh | Kit for the preparation of a pharmaceutical composition |
| US8541399B2 (en) | 2002-02-19 | 2013-09-24 | Resolution Chemicals Limited | Solvent-based sterilisation of pharmaceuticals |
| EP1481007B1 (en) | 2002-03-04 | 2007-01-24 | Nymox Corporation | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom |
| EP1495765A4 (en) | 2002-04-12 | 2005-08-03 | Ajinomoto Kk | COMPOSITION FOR PREVENTING ARTERIOSCLEROSIS |
| ITMI20020808A1 (it) * | 2002-04-17 | 2003-10-17 | Chiesi Farma Spa | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione |
| JP4364486B2 (ja) | 2002-07-02 | 2009-11-18 | 帝人株式会社 | 無菌水性懸濁製剤 |
| US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
| BR0313611A (pt) * | 2002-08-30 | 2005-06-21 | Altana Pharma Ag | Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica |
| JP3857708B2 (ja) | 2002-09-24 | 2006-12-13 | 富士通株式会社 | 歪み波形制御装置、歪み規制部材、歪み波形制御装置の歪み波形制御方法、及び歪み波形制御プログラム |
| CA2500908A1 (en) | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| ITMI20022674A1 (it) * | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
| EP1454636A1 (en) | 2003-03-04 | 2004-09-08 | Dompé S.P.A. | Sterilization of glucocorticoid drug particles for pulmonary delivery |
| MY143936A (en) | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
| TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| JP5618452B2 (ja) * | 2003-09-16 | 2014-11-05 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングＴａｋｅｄａ ＧｍｂＨ | 呼吸器疾患の治療のためのシクレソニドの使用 |
| DE10347994A1 (de) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| US7892483B2 (en) | 2004-03-12 | 2011-02-22 | Cipla Limited | Sterilization process |
| GB0410995D0 (en) | 2004-05-17 | 2004-06-23 | Norton Healthcare Ltd | Heat sterilization of glucocorticosteroids |
| ITSA20040012A1 (it) | 2004-09-07 | 2004-12-07 | Genetec S P A | Processo di sterilizzazione di un glucocorticosteroide. |
| GB0425266D0 (en) | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
-
2004
- 2004-12-10 PE PE2004001247A patent/PE20050941A1/es active IP Right Grant
- 2004-12-14 MY MYPI20045134A patent/MY159377A/en unknown
- 2004-12-15 CA CA2549038A patent/CA2549038C/en not_active Expired - Fee Related
- 2004-12-15 US US10/582,499 patent/US20070117783A1/en not_active Abandoned
- 2004-12-15 WO PCT/EP2004/053495 patent/WO2005058935A2/en not_active Ceased
- 2004-12-15 EP EP10173237.8A patent/EP2319858B1/en not_active Expired - Lifetime
- 2004-12-15 AR ARP040104661A patent/AR046892A1/es not_active Application Discontinuation
- 2004-12-15 JP JP2006544438A patent/JP5001657B2/ja not_active Expired - Lifetime
- 2004-12-15 CN CNB2004800368287A patent/CN100513417C/zh not_active Expired - Lifetime
- 2004-12-15 BR BRPI0416854A patent/BRPI0416854B8/pt active IP Right Grant
- 2004-12-15 UA UAA200607589A patent/UA87123C2/uk unknown
- 2004-12-15 NZ NZ547217A patent/NZ547217A/en not_active IP Right Cessation
- 2004-12-15 EA EA200601091A patent/EA012388B1/ru not_active IP Right Cessation
- 2004-12-15 EP EP04804847A patent/EP1697398B1/en not_active Expired - Lifetime
- 2004-12-15 AU AU2004298447A patent/AU2004298447B2/en not_active Expired
- 2004-12-15 KR KR1020067013760A patent/KR101086095B1/ko not_active Expired - Lifetime
- 2004-12-16 TW TW093139206A patent/TWI350757B/zh not_active IP Right Cessation
-
2006
- 2006-05-07 IL IL175461A patent/IL175461A/en active IP Right Grant
- 2006-05-11 ZA ZA200603768A patent/ZA200603768B/en unknown
- 2006-06-05 EC EC2006006608A patent/ECSP066608A/es unknown
- 2006-06-07 CO CO06054801A patent/CO5700832A2/es active IP Right Grant
- 2006-06-30 NO NO20063047A patent/NO337225B1/no unknown
-
2015
- 2015-09-25 US US14/865,637 patent/US11052042B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6392036B1 (en) * | 1997-11-14 | 2002-05-21 | Astrazeneca Ab | Dry heat sterilization of a glucocorticosteroid |
| WO2004004739A1 (en) * | 2002-07-02 | 2004-01-15 | Altana Pharma Ag | Ciclesonide-containing sterile aqueous suspension |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11052042B2 (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| EP2704724B1 (en) | Improved suspension formulation of beclometasone dipropionate for administration by inhalation | |
| AU2024227441A1 (en) | Aqueous nebulization composition | |
| US20190290633A1 (en) | Tiotropium Inhalation Solution for Nebulization | |
| MXPA06006537A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| HK1098486B (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| WO2019084478A1 (en) | TIOTROPIUM INHALATION SOLUTION TO BE NEBULIZED |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ASTRAZENECA AB, SE |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: COVIS PHARMA B.V., CH |
|
| CREP | Change of representative |
Representative=s name: BRYN AARFLOT AS, STORTINGSGATA 8, 0161 OSLO, NORGE |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: COVIS PHARMA GMBH, CH |